Humana Inc vs Vanguard Growth Index Fund ETF — how do they compare? Humana Inc trades at $445 (market cap $47.61B), while Vanguard Growth Index Fund ETF trades at $91.99 (market cap $384.60B). The key difference: Vanguard Growth Index Fund ETF is far larger — about 8.1× Humana Inc's market cap, and Humana Inc pays a 0.89% dividend while Vanguard Growth Index Fund ETF pays none. Which is the better fit depends on your goals — on Pluang, investors hold Humana Inc for 53 Days and Vanguard Growth Index Fund ETF for 47 Days on average.
| HUM | VUG | |
|---|---|---|
Market Cap | $47.61B | $384.60B |
Volume | 1,827,332 | 4,760,473 |
Sector | Health | Sector/Thematic |
52-Week High | $409.85 | $92.64 |
52-Week Low | $163.67 | $70.00 |
Typical Hold Time | 53 Days | 47 Days |
Enterprise Value | $54.97B | — |
Dividend Yield | 0.89% | — |
Signals from Pluang's Aura AI — not financial advice
Humana (HUM) trades at $387.12, down 4.24% today, but maintains a bullish technical outlook with strong institutional support. The stock shows mixed fundamentals with revenue growth to $129.66B in 2025 but declining profit margins at 0.88%. Recent analyst upgrades, including Barclays' $515 target on September 25, 2026, highlight optimism despite ongoing Medicare Advantage plan adjustments affecting member transitions.
Investment outlook remains cautiously optimistic with a consensus price target of $432.63 offering 12% upside. Risks include margin compression, regulatory scrutiny from Medicare billing practices, and competitive pressures in managed care. The company's strong cash position of $20.44B and consistent dividend payments provide stability amid enrollment volatility.
VUG trades at $92.42, down 0.24% with bullish technical signals from moving averages but bearish oscillators suggesting potential overbought conditions. The ETF maintains strong long-term performance with 12% average annual returns since inception, though current RSI levels indicate near-term caution. Recent news highlights VUG's concentration in mega-cap technology stocks like Nvidia, Apple, and Microsoft, which comprise over 36% of holdings.
Long-term growth prospects remain favorable given VUG's historical outperformance and low 0.03% expense ratio. However, significant concentration risk in technology sector and elevated RSI levels present near-term headwinds. The ETF's value proposition centers on cost-efficient exposure to large-cap growth stocks for investors with multi-decade time horizons.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
No sentiment data available yet.
Latest headlines on both assets
Humana is one of the largest private health insurers in the U.S. with a focus on administering Medicare Advantage plans. The firm has built a niche specializing in government-sponsored programs, with nearly all its medical membership stemming from individual and group Medicare Advantage, Medicaid, and the military's Tricare program. The firm is also a leader in stand-alone prescription drug plans for seniors enrolled in traditional fee-for-service Medicare. Humana offers employer-based plans primarily for small businesses along with specialty insurance offerings such as dental, vision, and life. Beyond medical insurance, the company provides other healthcare services, including primary-care services, at-home services, and pharmacy benefit management.
Read more on HUM →VUG is an index-based ETF that tracks the CRSP US Large Cap Growth Index, providing concentrated exposure to the largest and fastest-growing companies in the United States. It focuses on stocks with high growth potential across tech, communication, and consumer sectors, serving as a low-cost, high-conviction core holding for long-term capital appreciation.
Read more on VUG →